Arcutis Biotherapeutics, Inc.
ARQT
$13.01
$0.050.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 74.03% | 20.63% | -47.91% | 46.62% | -48.07% |
| Total Depreciation and Amortization | -68.02% | 307.98% | -1.96% | -7.01% | -0.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.91% | -17.14% | 25.57% | -4.12% | -3.45% |
| Change in Net Operating Assets | 58.81% | 10.85% | 21.59% | -1,424.09% | 104.48% |
| Cash from Operations | 97.84% | 23.12% | -42.77% | 43.81% | -27.87% |
| Capital Expenditure | 100.00% | -- | -- | -- | 90.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.93% | 236.67% | -116.53% | 53.85% | -236.32% |
| Cash from Investing | -58.86% | 236.44% | -116.53% | 53.85% | -236.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 557.11% | -72.92% | -99.10% | 62.92% | 11,352.02% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -24,823.60% | -72.92% | -99.10% | 62.92% | 11,352.02% |
| Foreign Exchange rate Adjustments | -338.78% | 476.92% | 64.38% | -207.35% | 190.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -225.57% | 147.80% | -204.38% | 631.59% | -909.21% |